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ABSTRACT
Turner syndrome (TS) is one of the most common types of aneuploidy among humans, and is present in 1:2000 newborns with female phenotype. 
Cytogenetically, the syndrome is characterized by sex chromosome monosomy (45,X), which is present in 50-60% of the cases. The other cases present 
mosaicism, with a 45,X cell line accompanied by one or more other cell lines with a complete or structurally abnormal X or Y chromosome. The presence 
of Y-chromosome material in patients with dysgenetic gonads increases the risk of gonadal tumors, especially gonadoblastoma. The greatest concern is 
the high risk of developing gonadoblastoma or other tumors and virilization during puberty if chromosome Y-specific sequences are present. The role of 
the Y chromosome in human oncogenesis is still controversial. Even though gonadoblastoma is a benign tumor, it can undergo transformation into invasive 
dysgerminoma in 60% of the cases, and also into other, malignant forms of germ cell tumors. Although some authors have questioned the high incidence 
of gonadoblastoma (around 30%), the risk of developing any kind of gonadal lesion, whether tumoral or not, justifies investigation of Y-chromosome 
sequences by means of the polymerase chain reaction (PCR), a highly sensitive, low-cost and easy-to-perform technique. In conclusion, mosaicism of 
both the X and the Y chromosome is a common finding in TS, and detection of Y-chromosome-specific sequences in patients, regardless of their karyotype, 
is necessary in order to prevent the development of gonadal lesions.
RESUMO
A síndrome de Turner (ST) é uma das aneuploidias mais comuns em humanos e está presente em 1:2000 recém-nascidas com fenótipo feminino. 
Citogeneticamente, a síndrome é caracterizada por uma monossomia de cromossomo sexual (45,X) em 50-60% dos casos. Os demais casos apresentam 
mosaicismo com uma linhagem celular 45,X acompanhada de outra(s) com o cromossomo X ou Y íntegros ou com alterações estruturais. A presença 
de material do cromossomo Y em pacientes com gônadas disgenéticas aumenta o risco de tumores gonadais, especialmente gonadoblastoma. A 
consideração mais importante diz respeito ao elevado risco de desenvolvimento de gonadoblastoma ou outros tumores e a virilização na puberdade 
se sequências cromossomo Y-específicas estiverem presentes. O papel do cromossomo Y na oncogênese dos cânceres humanos ainda é controverso. 
Apesar de o gonadoblastoma ser um tumor benigno, ele pode transformar-se num disgerminoma invasivo em 60% dos casos e também em outras 
formas malignas de tumores de células germinativas. Apesar de alguns autores questionarem a alta incidência (em torno de 30%) de gonadoblastoma, 
o risco do desenvolvimento de qualquer tipo de lesão gonadal, tumoral ou não, justifica a pesquisa de sequências do cromossomo Y por PCR (reação de 
polimerase em cadeia), técnica de alta sensibilidade, baixo custo e fácil execução. Em conclusão, o mosaicismo cromossômico tanto do X como do Y é 
um fato comum na ST e a detecção de sequências cromossomo Y-específicas nas portadoras, independentemente do seu cariótipo, é necessária para 
prevenir o desenvolvimento de lesões gonadais.
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INTRODUCTION
In 1938, Henry Turner1 described a group of female adolescents 
with primary amenorrhea, sexual infantilism and short stature. The pa-
tients also presented cubitus valgus, webbed neck, widely spaced nipples, 
low posterior hairline and lymphedema of hands and feet. Four years 
later, Varney et al.2 and Albright et al.,3 independently from each other, 
studied patients with clinical signs resembling those described by Turner 
and demonstrated that, after puberty, they presented a high level of uri-
nary gonadotropins, thus establishing that there was an abnormality of 
gonadal function rather than a hypothalamic or hypophyseal deficiency. 
In l944, Wilkins and Fleischmann4 performed histological analyses and 
observed that patients with the clinical signs described by Turner,1 Var-
ney et al.2 and Albright et al.3 probably had streak gonads, and that all 
those authors were studying the same syndrome: Turner’s syndrome.
Turner’s syndrome (TS) is one of the most common types of ane-
uploidy in humans, and is present in 1:2000 newborns with female 
phenotype.5,6 The first karyotype investigation in a patient with TS was 
performed in England, in 1959, by Ford et al.7 These authors were able 
to describe X-chromosome monosomy, i.e. the 45,X karyotype, which is 
the type most frequently found among patients with TS8 (Figure 1).
CLINICAL CHARACTERISTICS
Individuals with TS present extremely variable phenotypes. Despite 
their undifferentiated gonads, they have clearly female external and in-
ternal genitals. However, their uterus is small, since its full develop-
ment depends on hormonal stimuli. The gonads are usually two fibrous 
streaks in which no germ cells or follicular formations, but only tissue 
resembling the stroma of the ovarian cortex is detected.9,10
Other signs that are found may include dysmorphic auricles with 
the longitudinal axis in an oblique position, eyelids with antimongoloid 
slanting, internal epicanthal folds, high-arched palate, retrognathism, 
widely spaced nipples, short sternum, cardiovascular malformations 
(the most common are coarctation of the aorta and ventricular septum 
defects), renal malformations (such as horseshoe kidneys, urethral du-
plication and unilateral kidney agenesis) and hypoplasia of the fourth 
or fifth metacarpal and metatarsal bones. Breast growth in TS patients 
is much slower than in normal individuals. Since women with TS pres-
ent gonadal dysgenesis, the endocrine changes that are typical of pu-
berty do not occur, and reports of primary amenorrhea are frequent9,10 
(Figure 2).11
In 1997, Rao et al.12 isolated a gene named SHOX (short stature 
homeobox gene) that is located at Xp22 and Yp11.3, in the pseudoau-
tosomal region of the sex chromosomes. The haploinsufficiency of this 
gene is believed to be responsible for the short stature and for several 
skeletal anomalies presented by TS patients.
TS patients present high frequencies of autoimmune diseases, par-
ticularly hypothyroidism, celiac disease and diabetes mellitus, which so 
far remain unexplained.5,10,13 Moreover, some authors have suggested 
that there is a higher risk of autoimmune diabetes among TS patients 
with karyotypes presenting an X isochromosome.4 An isochromosome 
of the long arm of the X chromosome (Xq) results from deletion of the 
short arm and duplication of the long arm of one of the X chromo-
somes, and this is the most common structural abnormality found in 
TS cases.
GENETIC CHARACTERISTICS
Cytogenetically, the Turner syndrome is characterized by sex chro-
mosome monosomy (45,X) in phenotypically female individuals. This 
karyotype is found in 50-60% of the cases.5,14 The other cases are mo-
saics with a 45,X cell line accompanied by others with two or more X 
chromosomes or with structural anomalies. Such structural anomalies 
of the X chromosome (isochromosomes of the long arm, dicentric chro-
mosomes, deletion of the short arm or ring chromosomes) are present 
in approximately 30% of the cases, in homogeneous karyotypes or in 
mosaics that include a 45,X cell line. Finally, around 5% are accounted 
for by patients with structural abnormalities of the Y chromosome (iso-
chromosomes of the long arm and dicentric chromosomes) and mosaics 
that include a cell line accompanied by others with at least one Y chro-
mosome, whether complete or not.5,8
Data from the literature show that a second sex chromosome is 
necessary for the fetus to survive, and therefore virtually every liveborn 
Figure 1. Turner syndrome karyotype (45,X). Figure 2. Clinical-phenotypic findings in Turner.11 
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45,X individual should present more than one cell karyotype line, thus 
constituting a mosaic.15 This condition would be necessary for at least 
some organs, during a certain period of embryogenesis. This hypothesis 
is based on two main points: the frequency of sex chromosome mosa-
icism is much higher in liveborn infants with TS than in aborted fetus-
es; and an estimate that approximately 99% of the embryos with a pure 
45,X karyotype die in utero.16,17
Furthermore, comparison with other numerical chromosomal 
anomalies, such as Down syndrome or chromosome 18 trisomy, reveals 
that the incidence of TS does not increase with maternal age.18,19 These 
findings argue against meiotic nondisjunction as the main mechanism 
for the generation of a 45,X karyotype. Clinically, in contrast to oth-
er chromosomal syndromes, even patients with a pure 45,X karyotype 
present completely distinct phenotypes. Except for short stature, which 
seems to be a general characteristic, all other findings are inconsistent. 
One of the possible explanations for this fact might be undetected mo-
saicism, since the diagnosis is usually made by analyzing between 5 and 
30 peripheral blood lymphocytes to determine the karyotype,20 and the 
second cell line is often present as a proportion of no more than 1 to 2% 
of the individual’s cells.
In around 99% of human conceptuses with a 45,X karyotype, nat-
ural loss occurs during the first stage of embryonic development.15,17 
Only 1% of these fertilizations are successful, and they generally display 
TS characteristics.1 Both embryonic mortality and the characteristic TS 
phenotype are considered to result from monosomy of genes that are 
common to the X and Y chromosomes (pseudoautosomal region).21 In 
women, it is clear that these genes are expressed both in the active and 
in the inactivated X chromosome, as a means of ensuring the proper 
amount of gene product. It is believed that one or more of these genes 
are responsible for TS.22,23
DETECTION OF MOSAICISM
The detection of mosaicism is determined mainly by four factors: 
the type and number of tissues analyzed; the number of cells studied;16 
the sensitivity of the techniques used; and the possibility of selection, 
which can result in disappearance of cell lines.15,24 A small percent-
age of mosaicism cannot be detected by the classical cytogenetic tech-
nique, because this kind of analysis requires a large number of cells. 
The use of molecular techniques such as fluorescence in situ hybridiza-
tion (FISH) and the polymerase chain reaction (PCR) substantially im-
proves the detection of low-frequency cell lines and possible structural 
abnormalities.23,25
Peripheral blood lymphocytes are generally the material of choice 
for cytogenetic analysis on patients suspected of having TS, since this 
tissue is easy to obtain. In routine laboratory diagnosis, the classical cy-
togenetic analysis is performed in thirty metaphases, which allows de-
tection of 10% mosaicism. If the hypothesis that all patients with Turn-
er syndrome carry mosaicism is true, it is possible that cell lines that 
are present in blood at frequencies below 10% go undetected by this 
method.26
Another issue to be considered is the analysis of different tissues, 
since mosaicism may not be detected in peripheral blood, but may be 
significant in tissue samples of different embryonic origin, for example 
oral mucosa.26-29 
The presence of Y-chromosome material in individuals with TS can 
be investigated both cytogenetically and by using various molecular 
approaches.30 The latter presents the advantages of not needing cell 
cultures and requiring only a rather small amount of material. Thus, 
the use of molecular methods for identifying Y-chromosome-specif-
ic sequences has become an indispensable tool for detecting hidden 
mosaicism.31-34 
Nazarenko et al.35 also observed that cytogenetic analysis may not 
provide precise information on the presence of chromosomal mosaicism 
in patients with TS. Additional analysis of cells from tissues of different 
embryonic origins (mesodermal lymphocytes and ectodermal oral epi-
thelium cells, for instance) allowed greater precision in defining the cy-
togenetic diagnosis. FISH analysis with a probe for the X chromosome 
allowed a more accurate result, thus showing that 29% out of fifty pa-
tients with pure X monosomy detected by ordinary karyotyping actu-
ally presented mosaics. In addition, according to these authors, distinct 
chromosomal constitution was observed in different tissues from the 
same individual, thereby highlighting the possibility that chromosomal 
abnormalities or the presence of a second sex chromosome may be ab-
sent in blood but present in other tissues.
According to Mendes et al.,36 mosaicism is present in 25% of TS 
karyotypes. Y-chromosome-specific sequences can be observed in ap-
proximately 40% of these cases. According to López et al.,32 the diffi-
culty in comparing the frequency of Y-chromosome-specific sequences 
or of the Y chromosome itself in patients with TS is due mainly to the 
variability in the number of patients analyzed; the frequency of mosa-
icism with a normal and an abnormal X chromosome; the number of 
cases with marker chromosomes; the molecular methodology applied 
in each study; and the Y-chromosome-specific sequences studied. These 
authors used a combination of classical cytogenetics and molecular de-
oxyribonucleic acid (DNA) analysis methods to study the presence of 
Y-chromosome-derived material in 50 patients with Turner syndrome. 
Their molecular results revealed that the frequency of Y-chromosome-
specific sequences was 12%, whereas it had previously been found to be 
2%, using classical cytogenetics.
Chu et al.33 stated that PCR is more effective than cytogenetic anal-
ysis for detecting hidden mosaicism involving the Y chromosome, and 
may be even more effective using a multiple-tissue approach, thereby 
raising the chances of revealing mosaicism, if present.
Guedes et al.37 studied a girl who, despite her 45,X/46,X,der(Y) 
karyotype, displayed no signs of virilization and/or clinical features of 
TS, except for decreased growth speed. After prophylactic gonadectomy, 
in view of the risk of developing gonadoblastoma, samples from blood 
and gonad material were studied by means of FISH and PCR, to search 
for Y-chromosome-specific sequences. These analyses revealed that the 
Y-derived chromosome was actually a Yp isodicentric chromosome and 
that there was a significant difference in the distribution of the mosa-
icism between the two tissues studied. Although 97.5% of the cells an-
alyzed in peripheral blood were 46,X,idic(Yp) with duplication of the 
SRY gene, this did not determine any degree of male sex differentiation, 
since 60% of the cells analyzed in the gonadal tissue were 45,X, thus 
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suggesting that in this patient, the tissue-specific mosaicism contributed 
towards female sex development.
Y CHROMOSOME AND RISK OF GONADAL 
TUMOR DEVELOPMENT
Abnormalities in gonad organogenesis can lead to the development 
of gonadal tumors,38 especially in patients with dysgenetic gonads.39 
Patients with disorders of sexual development are at increased risk of 
developing tumors originating from germ lines, also known as germ-
cell tumors.40 Several risk factors have been identified for these kinds of 
germ-cell tumors, particularly those relating to gonads, including cryp-
torchidism and gonadal dysgenesis.40-42
The precursor lesion for dysgenetic gonad tumors is named gonado-
blastoma.41 This has the potential to progress towards invasive germ-cell 
tumors, particularly dysgerminoma, and, less frequently, towards com-
ponents of other tumors, such as embryonic carcinoma, teratoma, yolk 
sac tumor and choriocarcinoma.43
Gonadoblastoma is a mixed tumor of undifferentiated cells that re-
capitulates gonadal development41 and is able to originate dysgermino-
ma in 60% of the cases.44 Hyperandrogenism is a phenomenon com-
monly associated with gonadoblastoma, especially in cases of coexis-
tence with dysgerminoma.44 
There is strong evidence that gonadoblastoma results from a disor-
der in germ cell maturation. This model is supported by epidemiologi-
cal and morphological observations, such as the presence of immuno-
histochemical germ cell markers (placental alkaline phosphatase) and 
proto-oncogenes (c-KIT).45-47
The genes SRY16,20,32,36,48-56 and DYZ316,32,34,48-51,53,55-57 are the se-
quences most commonly used in studies. Controversy still exists regard-
ing which Y-chromosome markers are the most relevant. In general, the 
SRY gene is the sequence most used, because of its location and impor-
tant role in the sex differentiation cascade.58  
However, with the identification of novel genes on the Y chromo-
some and the so-far unconfirmed suspicion that there is a specific gene 
associated with the development of gonadoblastoma, other regions have 
been associated with the development of this tumor.59
GBY (gonadoblastoma locus on the Y chromosome) is a gene that 
is assumed to be related to the presence of tumors originating from dys-
genetic gonads. This gene is probably located within a small region of 
the short arm of the Y chromosome, close to the centromere.59 TSPY 
(testis-specific protein Y-encoded) is a candidate gene for the GBY locus, 
which is possibly related to the development of gonadoblastoma and the 
involvement of a specific region of the Y chromosome.60,61 Hildenbrand 
et al.62 studied a patient with TS and a 45,X/46,X,+mar karyotype who 
developed unilateral gonadoblastoma. Cytogenetic and molecular stud-
ies confirmed that the marker was derived from the Y chromosome. 
These authors investigated the gonad material by immunohistochemis-
try for expression of the TSPY gene, and the results revealed a high level 
of TSPY protein expression.
Furthermore, the POU5F1 (OCT4) gene, located at 6p21.31, is ex-
pressed in pluripotent stem cells and germ cells in mice and humans.63-68 
Extensive immunohistochemical screening for POU5F1 protein expres-
sion has been carried out on several types of germ cell tumors using mi-
croarrays and has shown that their immunoreactivity is only detectable 
in gonadoblastoma, seminoma, dysgerminoma and embryonic carcino-
ma cells.43
Considering that detection of Y-chromosome-specific sequences in 
patients with Turner syndrome is necessary in order to prevent the de-
velopment of gonadoblastoma,69 clinical characteristics such as signs of 
hyperandrogenism should also be considered in deciding on the thera-
peutic approach to be adopted for such patients. This is important be-
cause the administration of growth hormone (somatotropin) to patients 
carrying Y-chromosome fragments may lead to the development of this 
neoplasm or other androgen-secreting tumors,70 although this is still a 
controversial matter. Treatment with growth hormone is indicated for 
TS patients and the results have been satisfactory, but the long-term ef-
fects resulting from this treatment are still under observation.71
The SRY gene, whose major role in sex determination and differen-
tiation has been well known ever since the first studies of Page,60 rep-
resents an intermediate link in the signaling chain that occurs during 
embryonic development. It serves as an activator and is also regulated 
by several genes (SOX-9; WT-1; SF-1, etc.). This gene is of fundamen-
tal importance in cell differentiation and, consequently, in determining 
the gonadal microenvironment. The interaction starts in the presence 
of androgens.
It has traditionally been recommended that a search for Y-chromo-
some fragments in TS should only be performed under two circum-
stances: when there are signs of virilization and/or when there is a mark-
er chromosome not identified by classical cytogenetics.72,73 Nevertheless, 
when Canto et al.74 used PCR to study 107 Turner syndrome patients 
with a 45,X karyotype, they identified Y-chromosome material in ten 
(9.3%) of them. Prophylactic gonadectomy was indicated, and two of 
the six patients who agreed to undergo the surgery presented gonado-
blastoma, thus indicating an incidence of 33%.
Similarly, Bianco et al.34 studied different tissue samples from 20 TS 
patients by means of PCR and found that seven (35%) of the 45,X pa-
tients presented Y-chromosome-specific sequences in at least one of the 
tissues studied. Four (14%) of these patients underwent prophylactic 
gonadectomy, and bilateral gonadoblastoma was found in a 16-year-old 
girl. In this case, the presence of Y-chromosome sequences was not as-
sociated with virilization, thus reinforcing the idea that absence of this 
characteristic does not rule out the possibility of the presence of hidden 
Y chromosome fragments.
In addition, Bianco et al.55 investigated the presence of Y-chromo-
some mosaicism (SRY, TSPY and DYZE) in 87 TS patients by means 
of PCR, along with its association with the development of gonadal 
tumors and/or nontumoral androgen-producing lesions. The data re-
vealed hidden Y-chromosome mosaicism in 18.5% of the patients. The 
SRY sequence was detected in all of these patients, while 4.6% of them 
presented the DYZ3 repeat region and 4.6% of them presented the 
TSPY gene. Eleven of the patients with Y-positive sequences agreed to 
undergo prophylactic surgery. In two cases, bilateral gonadoblastoma 
was found and, in another case, histopathological analysis on the go-
nads revealed hilus cell hyperplasia. In a further case, hilus cell hyper-
Y chromosome in Turner syndrome: review of the literature 
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plasia and stromal luteoma were found. These authors concluded that 
a systematic search for hidden Y-chromosome mosaicism, especially for 
the SRY gene, in Turner syndrome patients, was justified because of the 
possibility of preventing gonadal lesions.
CONCLUSION
The role of the Y chromosome in human oncogenesis is still contro-
versial. However, identification of Y-chromosome mosaicism is clinically 
important because of the high risk that tumors such as gonadoblastoma 
or other, nontumoral androgen-producing lesions might develop in the 
dysgenetic gonads of patients with hidden Y-chromosome mosaicism or 
Y-chromosome-specific sequences. Although gonadoblastoma is a be-
nign tumor, it can undergo transformation into invasive dysgerminoma 
in 60% of the cases, and can also turn into other malignant forms of 
germ-cell tumors. Even though some authors have questioned the high 
incidence of gonadoblastoma (around 30%), the possibility that some 
kind of gonadal lesion might develop, whether tumoral or not, justifies 
investigation of Y-chromosome-specific sequences by means of PCR, 
which is a highly sensitive, low cost and easy-to-perform technique.
In conclusion, mosaicism of both the X and the Y chromosome is 
a common finding in TS, and detection of Y-chromosome-specific se-
quences in such patients, regardless of their karyotype, is necessary in 
order to prevent the development of gonadal lesions. 
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